Sezary Syndrome × Ondansetron × Clear all
NCT00795769 2017-05-23

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Completed
49 enrolled 4 charts
NCT00248547 2017-05-09

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

OHSU Knight Cancer Institute

Phase NA Completed
40 enrolled 8 charts
NCT00006348 2016-07-06

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Alliance for Clinical Trials in Oncology

Phase 3 Completed
100 enrolled
NCT00499668 2013-04-02

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Vanderbilt-Ingram Cancer Center

Phase NA Withdrawn